Therapeutic and diagnostic Morphomers™ enable AC Immune’s unique precision medicine approach for neurodegenerative diseases
Webinar will take place on
During the webinar, members of the AC Immune Management and Research and Development Teams will discuss the unique benefits of the Company’s innovative Morphomer™ technology platform, which accelerates the design, synthesis, and development of CNS-optimized, conformation-specific small molecules directed against pathological proteins. The platform has produced multiple clinically validated therapeutic and diagnostic candidates that bind selectively to target proteins intracellularly, at the earliest stages of disease.
The current Morphomer™ pipeline includes two clinical-stage diagnostic candidates (Tau-PET tracer and alpha-synuclein-PET tracer), and one therapeutic candidate that has completed Phase 1 (Morphomer™ Tau ACI-3024). Additional first-in-class Morphomer™-derived therapeutic and diagnostic candidates targeting Tau, alpha-synuclein, TDP-43 and NLRP3-ASC are in preclinical development. Together with the Company’s SupraAntigen™-derived therapeutic antibody and vaccine candidates, AC Immune’s comprehensive Morphomer™ pipeline enables a differentiated Precision Medicine approach against multiple key proteins by pairing the Company’s targeted therapeutics with proprietary companion diagnostics.
Following the formal presentations, there will be an interactive virtual roundtable discussion between the audience and the AC Immune Management and Research and Development Teams.
Chief Executive Officer
Chief Scientific Officer
Life Cycle Leader
Group Leader, In vivo Pharmacology and Non-Clinical Safety
For further information, please contact:
|Head of Investor Relations
Phone: +1 917 809 0814
LaVoie Health Science
Phone: +1 617 792 3937
Phone: +41 79 367 6254
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the
Source: AC Immune SA